The Silent Pandemic: Confronting Antimicrobial Resistance

Executive Summary

Antimicrobial resistance is a slow-moving pandemic that already kills more people each year than HIV/AIDS or malaria, yet attracts a fraction of the attention. As bacteria, fungi, and parasites evolve to survive the drugs designed to kill them, the foundations of modern medicine — safe surgery, childbirth, cancer treatment, organ transplantation — begin to erode. The problem is uniquely hard: resistance is an evolutionary inevitability that can be slowed but never eliminated, and the market for new antibiotics has collapsed precisely because effective stewardship requires using them sparingly.

The Scale of the Problem

In 2019, bacterial AMR was directly responsible for an estimated 1.27 million deaths and associated with 4.95 million deaths globally — more than the toll of HIV/AIDS and malaria combined. A 2024 analysis projects roughly 39 million cumulative deaths directly attributable to AMR between 2025 and 2050. The burden falls hardest on low- and middle-income countries with limited access to second-line drugs and weak diagnostic infrastructure.

Beyond mortality, AMR imposes vast economic costs through prolonged hospital stays, more expensive treatments, and lost productivity — the World Bank has warned it could push tens of millions into extreme poverty.

Why This Is Hard (Low Tractability)

• A broken R&D market: New antibiotics are commercially unattractive. Good stewardship means reserving them, which destroys the revenue model. Most major pharmaceutical companies have exited antibiotic development entirely.
• Evolutionary inevitability: Resistance cannot be permanently "solved." Any solution must be a perpetual race, requiring sustained investment indefinitely.
• The One Health interface: Roughly two-thirds of global antibiotic use is in agriculture. Addressing AMR requires coordinated action across human health, veterinary medicine, and environmental policy.
• Global coordination: Resistance respects no borders. Gains in one country can be undone by overuse in another.

The Neglectedness Gap

Although AMR is a recognized WHO and G7 priority — with bodies like CARB-X and GARDP and roughly $13.75 billion in public and philanthropic R&D commitments since 2017 — funding remains badly mismatched to a problem of this scale. Private antibiotic R&D investment has largely collapsed, and pull incentives to revive it remain underfunded and politically contested.

Tractable Interventions

1. Antibiotic stewardship programs in hospitals and clinics to preserve the drugs we still have.
2. Pull incentives — subscription-style "Netflix" payment models (piloted in the UK and proposed in the US PASTEUR Act) that decouple antibiotic revenue from sales volume.
3. Vaccines that prevent resistant infections from occurring in the first place.
4. Rapid diagnostics to ensure antibiotics are used only when needed and the right drug is chosen.
5. Agricultural reform to phase out growth-promotion antibiotic use and tighten veterinary prescribing.
6. Global surveillance (e.g., WHO GLASS) to track resistance patterns and target interventions.

Recommendations

1. Champion pull-incentive legislation to revive the antibiotic pipeline.
2. Fund stewardship and rapid diagnostics in high-burden, low-resource settings.
3. Support One Health coordination to curb agricultural overuse.
4. Invest in vaccines and infection-prevention as upstream resistance reducers.

Further Reading

• GRAM Project / IHME, "Global burden of bacterial antimicrobial resistance," The Lancet (2022, 2024)
• WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS)
• O'Neill, J., "Tackling Drug-Resistant Infections Globally" (Review on AMR, 2016)
• CARB-X and GARDP program reports